MCID: VSC003
MIFTS: 55

Visceral Leishmaniasis

Categories: Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

MalaCards integrated aliases for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 14
Leishmaniasis, Visceral 42 69
Kala-Azar 12 3
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 52

Classifications:



External Ids:

Disease Ontology 12 DOID:9146
ICD10 33 B55.0 B55.9
ICD9CM 35 085.0
MeSH 42 D007898
NCIt 47 C34771
SNOMED-CT 64 186803007 48115004
UMLS 69 C0023290

Summaries for Visceral Leishmaniasis

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a Neglected Tropical Disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to hemophagocytic lymphohistiocytosis and primary biliary cirrhosis. An important gene associated with Visceral Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Amphotericin B and deoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

Wikipedia : 72 Visceral leishmaniasis (VL), also known as kala-azar,black fever, and Dumdum fever, is the most severe... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 343)
id Related Disease Score Top Affiliating Genes
1 hemophagocytic lymphohistiocytosis 31.0 IFNG IL10 IL2 TNF
2 primary biliary cirrhosis 30.5 IL10 SLC11A1 TNF
3 polyarteritis nodosa 30.4 ALB IFNG TNF
4 membranoproliferative glomerulonephritis 30.0 IFNG IL2 TLR9 TNF
5 systemic lupus erythematosus 28.8 ALB IFNG IL10 IL2 IL4 TLR9
6 lymphoma 28.7 ALB FOXP3 IFNG IL10 IL2 IL4
7 rheumatoid arthritis 27.8 CXCL8 FOXP3 IFNG IL10 IL2 IL4
8 malaria 25.8 ALB CXCL8 FOXP3 IFNG IFNGR1 IL10
9 leishmaniasis 12.1
10 myoclonic astatic epilepsy 10.9 IFNG IL4
11 pure autonomic failure 10.9 IL10 TNF
12 eye accommodation disease 10.8 IFNG IL10 IL4
13 scirrhous adenocarcinoma 10.8 IL2 TNF
14 thelaziasis 10.8 IFNG IL10 IL4
15 acute ackee fruit intoxication 10.7 IL10 IL4 TNF
16 hypercalcinuria macular coloboma 10.7 IFNG IL4 TLR4
17 loiasis 10.7 IFNG IL10 IL4
18 lagophthalmos 10.7 IL10 IL4 TNF
19 congenital dyserythropoietic anemia 10.7 ALB TNF
20 graft-versus-host disease, protection against 10.7 IFNG IL10 IL2
21 ethmoid sinus cancer 10.7 IFNG SLC11A1 TLR4
22 liver leiomyoma 10.7 IL10 IL4 TNF
23 x-linked intellectual disability, van esch type 10.7 IFNG IL2 IL4
24 visual snow syndrome 10.7 IL2 IL4
25 psychologic dyspareunia 10.7 IFNG IL10 TNF
26 chronic graft versus host disease 10.7 IFNG IL10 IL2
27 conduct disorder 10.7 IFNG IL10 TNF
28 sternal cleft 10.7 IFNG TNF
29 phlyctenulosis 10.7 IL10 IL4 TNF
30 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.7 ALB IFNG IL10
31 bulbospinal polio 10.7 IFNG IL2 TLR4
32 gonadal disease 10.7 IFNG IL2 IL4
33 tonsil cancer 10.7 ALB IFNG IL10
34 urethra transitional cell carcinoma 10.7 IL10 SLC11A1 TNF
35 reardon wilson cavanagh syndrome 10.7 IFNG IL4 TNF
36 autoimmune polyglandular syndrome type 3 10.7 IFNG IL2 TNF
37 diabetic angiopathy 10.7 IL10 IL4
38 disease of mental health 10.7 IFNG IL10 TNF
39 noma 10.7 IL10 IL4 TNF
40 multiple familial trichoepithelioma 10.7 IL10 TNF
41 epidermolysis bullosa acquisita 10.7 ALB IFNG IL10
42 sezary's disease 10.7 IFNG IL10 IL2
43 extrahepatic bile duct adenocarcinoma 10.7 IFNG IL10 TNF
44 cornea cancer 10.6 IFNG IL10 TNF
45 parametritis 10.6 IFNG IL2 TNF
46 vulvar nodular hidradenoma 10.6 IFNG IL10 IL4
47 neutrophil-specific granule deficiency 10.6 IL10 TLR2
48 prothrombin thrombophilia 10.6 TLR2 TLR4
49 ovarian endometrioid cystadenoma 10.6 IL10 IL2 IL4
50 central nervous system origin vertigo 10.6 IFNG IL2 IL4

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:



Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 FOXP3 IFNG IFNGR1 IL10 IL2 IL27
2 digestive/alimentary MP:0005381 10.37 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
3 homeostasis/metabolism MP:0005376 10.37 ALB FOXP3 IFNG IFNGR1 IL10 IL2
4 immune system MP:0005387 10.36 FOXP3 IFNG IFNGR1 IL10 IL2 IL27
5 cellular MP:0005384 10.35 ALB FOXP3 IFNG IFNGR1 IL10 IL2
6 mortality/aging MP:0010768 10.33 TLR9 TNF TPI1 ALB FOXP3 IFNG
7 endocrine/exocrine gland MP:0005379 10.25 ALB FOXP3 IFNG IFNGR1 IL10 IL2
8 cardiovascular system MP:0005385 10.23 FOXP3 IFNG IFNGR1 IL10 IL2 NOS2
9 liver/biliary system MP:0005370 10.22 ALB FOXP3 IFNG IFNGR1 IL10 IL2
10 integument MP:0010771 10.15 FOXP3 IFNG IFNGR1 IL10 IL4 NOS2
11 neoplasm MP:0002006 10.1 SLC11A1 TLR2 TLR4 TNF ALB IFNG
12 muscle MP:0005369 9.98 TLR2 TLR4 TNF ALB IFNG IL10
13 normal MP:0002873 9.97 IFNG IL10 IL4 TLR2 TLR4 TPI1
14 renal/urinary system MP:0005367 9.97 ALB FOXP3 IFNG IFNGR1 IL4 NOS2
15 reproductive system MP:0005389 9.91 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
16 respiratory system MP:0005388 9.81 IL10 IL2 IL4 NOS2 TLR2 TLR4
17 skeleton MP:0005390 9.61 IFNG IFNGR1 IL10 IL4 NOS2 PGD
18 vision/eye MP:0005391 9.23 IFNG IL10 IL2 IL4 NOS2 TLR4

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1397-89-3 14956 5280965
2
deoxycholic acid Approved Phase 4,Phase 3 83-44-3 222528
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Paromomycin Approved, Investigational Phase 4,Phase 3,Early Phase 1 1263-89-4, 7542-37-2 165580
5
Miltefosine Approved Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Cholagogues and Choleretics Phase 4,Phase 3
14 Gastrointestinal Agents Phase 4,Phase 3
15 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1
16 meglumine antimoniate Phase 4,Early Phase 1
17 Anesthetics Phase 4
18 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
19 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
20
Pentamidine Approved Phase 3 100-33-4 4735
21
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
22 Tocopherol Approved, Nutraceutical Phase 3
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
24 Adjuvants, Immunologic Phase 2, Phase 3
25 Vaccines Phase 2, Phase 3, Phase 1
26 Vitamins Phase 3
27 Tocopherols Phase 3
28 Tocotrienols Phase 3
29 Tocotrienol Investigational, Nutraceutical Phase 3 6829-55-6
30 Fat Emulsions, Intravenous Phase 2
31 Parenteral Nutrition Solutions Phase 2
32 Pharmaceutical Solutions Phase 2
33 Soybean oil, phospholipid emulsion Phase 2
34 Antibodies Phase 1, Phase 2
35 Immunoglobulins Phase 1, Phase 2
36 Soy Bean Nutraceutical Phase 2
37 Thromboplastin Phase 1
38
Acetylcysteine Approved, Investigational 616-91-1 12035
39
Coal tar Approved 8007-45-2
40
Albendazole Approved, Vet_approved 54965-21-8 2082
41
Iron Approved 7439-89-6 23925
42
Zinc Approved 7440-66-6 32051 23994
43
Erythromycin Approved, Vet_approved 114-07-8 12560
44
Neomycin Approved, Vet_approved 1404-04-2 8378
45
Vitamin A Approved, Nutraceutical, Vet_approved 11103-57-4, 68-26-8 445354
46 Antidotes
47 Antioxidants
48 Antiviral Agents
49 Expectorants
50 N-monoacetylcystine

Interventional clinical trials:

(show top 50) (show all 57)

id Name Status NCT ID Phase Drugs
1 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
2 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
3 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
4 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
5 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
6 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Not yet recruiting NCT01566552 Phase 4 AMBISOME
7 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
8 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
9 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
10 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
11 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
12 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
13 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
14 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
15 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
16 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
17 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
18 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
19 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
20 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
21 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Active, not recruiting NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
22 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Not yet recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
23 A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion
24 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2 Liposomal amphotericin B (AmBisome®) and sodium stibogluconate;Liposomal amphotericin B + miltefosine;Miltefosine
25 Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
26 Combination Chemotherapy for the Treatment of Indian Kala-Azar Completed NCT00370825 Phase 2 Combination therapy with AmBisome and miltefosine
27 Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Completed NCT02431143 Phase 2 Miltefosine
28 A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis. Completed NCT00381394 Phase 2 sitamaquine
29 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
30 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2 Miltefosine;Miltefosine
31 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)
32 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Recruiting NCT02687971 Phase 2 Miltefosine
33 A Study of a New Leishmania Vaccine Candidate ChAd63-KH Recruiting NCT02894008 Phase 2 ChAd63-KH
34 Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Terminated NCT01980199 Phase 2 Fexinidazole
35 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2 Miltefosine: initially 2.5 mg/kg/day for 28 days
36 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL Terminated NCT00832208 Phase 2 Liposomal amphotericin B (Ambisome);Liposomal amphotericin B (Ambisome)
37 SCH708980 With and Without AmBisome for Visceral Leishmaniasis Withdrawn NCT01437020 Phase 1, Phase 2 SCH708980 Anti-IL-10 monoclonal;AmBisome
38 Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India Completed NCT00486382 Phase 1
39 Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers Completed NCT02071758 Phase 1
40 Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL Completed NCT00982774 Phase 1
41 Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Completed NCT01484548 Phase 1
42 Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine Unknown status NCT01138956 N-acetylcysteine;Pentavalent antimonial
43 Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia Completed NCT02148822
44 A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh Completed NCT01240473 Randomized trial for treatment of kala azar in Bangladesh
45 Immunogenetics of Visceral Leishmaniasis Completed NCT00342823
46 Amphotericin B Treatment in Visceral Leishmaniasis Completed NCT00310505 Amphotericin B deoxycholate given as daily administration
47 A Community Trial for Visceral Leishmaniasis (VL) Completed NCT01069198 Albendazole, Iron, Zinc and Vitamin A
48 An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01328457 Paromomycin sulfate
49 Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar Completed NCT00318721
50 Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis Completed NCT01050777 Early Phase 1 Liposomal meglumine antimoniate (Glucantime);Liposomal meglumine antimoniate;Liposomal Paromomycin;Placebo

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

39
Bone, Bone Marrow, Liver, Spleen, Testes, Skin, T Cells

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 810)
id Title Authors Year
1
Historical overview of infantile visceral leishmaniasis in El Agamy, Alexandria, Egypt. ( 28870535 )
2017
2
Hematological Characteristics of Yemeni Adults and Children with Visceral Leishmaniasis. Could Eosinopenia be a Suspicion Index? ( 28894565 )
2017
3
Childhood Visceral leishmaniasis: Distinctive Features and Diagnosis of a Re-Emerging Disease. An 11-Year Experience from a Tertiary Referral Center in Athens, Greece. ( 28938257 )
2017
4
Challenges in modeling complexity of neglected tropical diseases: a review of dynamics of visceral leishmaniasis in resource limited settings. ( 28936226 )
2017
5
Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway. ( 28900667 )
2017
6
Diagnosis of Mediterranean visceral leishmaniasis by detection of Leishmania-related antigen in urine and oral fluid samples. ( 28017861 )
2017
7
Novel PCR primers to diagnose visceral leishmaniasis using peripheral blood, spleen or bone marrow aspirates. ( 28942823 )
2017
8
Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. ( 28873394 )
2017
9
Temporal dynamics and Leishmania infantum infection prevalence of Phlebotomus perniciosus (Diptera, Phlebotominae) in highly endemic areas of visceral leishmaniasis in Tunisia. ( 28934263 )
2017
10
Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFI+-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis. ( 28883727 )
2017
11
Molecular targets and pathways for the treatment of visceral leishmaniasis. ( 28919438 )
2017
12
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. ( 28066878 )
2017
13
Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil. ( 28076469 )
2017
14
Serological tests fail to discriminate dogs with visceral leishmaniasis that transmit Leishmania infantum to the vector Lutzomyia longipalpis. ( 28954069 )
2017
15
Control of visceral leishmaniasis in Somalia: achievements in a challenging scenario, 2013a892015. ( 28945058 )
2017
16
Visceral leishmaniasis in two patients with IL-12p40 and IL-12RI^1 deficiencies. ( 27873456 )
2017
17
New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence. ( 28945751 )
2017
18
HIF-1I+ is a key regulator in potentiating suppressor activity and limiting the microbicidal capacity of MDSC-like cells during visceral leishmaniasis. ( 28892492 )
2017
19
The direct costs of treating human visceral leishmaniasis in Brazil. ( 28954068 )
2017
20
Adenosine generated by ectonucleotidases modulates the host immune system during visceral leishmaniasis. ( 28082236 )
2017
21
Characterization of Leishmania (L.) infantum chagasi in visceral leishmaniasis associated with hiv co-infection in Northeastern Brazil. ( 28902293 )
2017
22
Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. ( 28064069 )
2017
23
Visceral Leishmaniasis-Malaria Coinfection and Their Associated Factors in Patients Attending Metema Hospital, Northwest Ethiopia: Suggestion for Integrated Vector Management. ( 28932617 )
2017
24
Visceral leishmaniasis and HIV/AIDS in Brazil: Are we aware enough? ( 28945816 )
2017
25
Control of visceral leishmaniasis in Somalia: achievements in a challenging scenario, 2013a892015. ( 28949118 )
2017
26
Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field. ( 28063460 )
2017
27
Environmental suitability for Lutzomyia longipalpis in a subtropical city with a recently established visceral leishmaniasis transmission cycle, Argentina. ( 28953995 )
2017
28
Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. ( 28091623 )
2017
29
Comparative B-mode and Doppler renal ultrasonography with histopathological findings in dogs positive for canine visceral leishmaniasis. ( 27194210 )
2016
30
Xenodiagnosis on dogs with visceral leishmaniasis: Canine and sand fly aspects related to the parasite transmission. ( 27198788 )
2016
31
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. ( 27627654 )
2016
32
Transgenic T cell-specific expression of CXCR3 enhances splenic and hepatic T cell accumulation but does not affect the outcome of visceral leishmaniasis. ( 27614845 )
2016
33
An 8-year retrospective study of human visceral leishmaniasis. ( 27659611 )
2016
34
Correlations between peripheral parasite load and common clinical and laboratory alterations in dogs with visceral leishmaniasis. ( 27664450 )
2016
35
Survey of feline visceral leishmaniasis in Azarshahr area, north west of Iran, 2013. ( 27605767 )
2016
36
Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs. ( 27624408 )
2016
37
SLA-PGN primed dendritic cell based vaccination induces Th17 mediated protective immunity against experimental visceral leishmaniasis: a crucial role of PKCI^. ( 27150838 )
2016
38
Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions. ( 27965662 )
2016
39
Pancytopenia caused by visceral leishmaniasis in a patient immunosuppressed after cancer therapy. ( 27811190 )
2016
40
A Subset of Neutrophils Expressing Markers of Antigen Presenting Cells in Human Visceral Leishmaniasis. ( 27601622 )
2016
41
Detection of Leishmania donovani in peripheral blood of asymptomatic individuals in contact with patients with visceral leishmaniasis. ( 27198212 )
2016
42
An rK28-Based Immunoenzymatic Assay for the Diagnosis of Canine Visceral Leishmaniasis in Latin America. ( 27162270 )
2016
43
A case of pseudorheumatism with submasseteric abscess and HLH in a patient with visceral leishmaniasis: A diagnostic dilemma. ( 28035119 )
2016
44
Visceral leishmaniasis triggering (mimicking) macrophage activation syndrome in a patient with adult onset Still disease. ( 27813355 )
2016
45
Thick Smear is a Good Substitute for the Thin Smear in Parasitological Confirmation of Canine Visceral Leishmaniasis. ( 27162266 )
2016
46
Correction: Canine-Based Strategies for Prevention and Control of Visceral Leishmaniasis in Brazil. ( 27606898 )
2016
47
Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. ( 27645786 )
2016
48
Risk factors, representations and practices associated with emerging urban human visceral leishmaniasis in Posadas, Argentina. ( 27622625 )
2016
49
Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis. ( 27645930 )
2016
50
The effects of increased heme oxygenase-1 on the lymphoproliferative response in dogs with visceral leishmaniasis. ( 28065450 )
2016

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CXCL8 IFNG IFNGR1 IL10 IL2 IL27
2
Show member pathways
13.71 CXCL8 IFNG IFNGR1 IL10 IL2 IL4
3
Show member pathways
13.46 CXCL8 IL10 IL2 IL4 TLR2 TLR4
4
Show member pathways
13.43 CXCL8 IFNG IFNGR1 IL10 IL2 IL27
5
Show member pathways
13.28 IFNG IFNGR1 IL2 IL4 TLR2 TLR4
6
Show member pathways
13.04 CXCL8 NOS2 TLR2 TLR4 TLR9 TNF
7
Show member pathways
12.94 CXCL8 FOXP3 IFNG IL10 IL2 IL4
8
Show member pathways
12.88 CXCL8 IFNG IFNGR1 IL2 IL4 TLR2
9
Show member pathways
12.8 CXCL8 IFNG IFNGR1 IL10 IL2 NOS2
10
Show member pathways
12.74 IL2 TLR2 TLR4 TLR9 TNF
11
Show member pathways
12.71 IFNG IFNGR1 IL10 IL2 IL4 TNF
12
Show member pathways
12.65 IFNG IL10 IL2 NOS2 TNF
13 12.65 FOXP3 IFNG IL10 IL2 IL4 TLR2
14
Show member pathways
12.65 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
15
Show member pathways
12.58 IFNG IFNGR1 IL2 IL4 TNF
16
Show member pathways
12.5 IFNG IL10 IL2 IL4 TNF
17
Show member pathways
12.42 CXCL8 IFNG IL4 TLR2 TNF
18
Show member pathways
12.37 CXCL8 IFNG IFNGR1 NOS2 TLR4 TNF
19
Show member pathways
12.31 IFNG IFNGR1 IL10 IL2 IL4
20
Show member pathways
12.31 IFNG IFNGR1 IL10 IL4 NOS2 TLR2
21
Show member pathways
12.27 CXCL8 IFNG IL10 IL2 IL4 TNF
22 12.27 IFNG IFNGR1 NOS2 TLR2 TLR4 TLR9
23 12.22 IFNG IFNGR1 IL10 NOS2 TLR2 TLR4
24 12.12 IFNG IL10 IL2 IL4 TNF
25
Show member pathways
12.1 IL2 TLR2 TLR4 TLR9
26 12.1 CXCL8 IL10 IL4 NOS2 TNF
27 12.1 CXCL8 IFNG IL2 IL4 NOS2 TLR4
28
Show member pathways
12.05 IFNG IL2 IL4 NOS2
29
Show member pathways
12.04 IFNG IL4 TLR2 TLR4 TLR9
30
Show member pathways
12.03 CXCL8 IFNG IFNGR1 IL4 NOS2 TLR2
31 11.99 IFNG IFNGR1 NOS2 TLR4
32 11.99 CXCL8 IFNG TLR2 TLR4 TNF
33 11.96 IFNG IFNGR1 IL10 IL2
34 11.96 CXCL8 IFNG IFNGR1 NOS2 TLR4
35 11.93 CXCL8 IFNG IL10 NOS2 TLR2 TLR4
36 11.92 IFNG IL10 IL2 IL4 TNF
37 11.9 CXCL8 IFNG IL2 IL4
38 11.89 CXCL8 TLR4 TNF
39 11.89 CXCL8 IL10 NOS2 TLR4 TNF
40 11.88 CXCL8 IL2 TLR4
41
Show member pathways
11.88 CXCL8 FOXP3 TLR4
42 11.88 IFNG IL10 IL2 TLR9 TNF
43
Show member pathways
11.85 CXCL8 FOXP3 IFNG IL2 IL4 TNF
44 11.84 TLR2 TLR4 TLR9
45
Show member pathways
11.79 CXCL8 IFNG IL2 NOS2 TNF
46
Show member pathways
11.74 FOXP3 IL2 IL4
47 11.71 CXCL8 IL4 TNF
48 11.7 CXCL8 TLR2 TLR4 TNF
49
Show member pathways
11.69 IFNG IL2 TNF
50 11.66 IFNG NOS2 TLR2 TLR4 TNF

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ALB CXCL8 IFNG IL10 IL2 IL27
2 external side of plasma membrane GO:0009897 9.46 IFNG IL4 TLR4 TNF
3 extracellular space GO:0005615 9.32 ALB CXCL8 IFNG IL10 IL2 IL27

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TLR2 TLR4 TLR9 TNF
2 response to virus GO:0009615 9.97 FOXP3 IFNG IFNGR1 TNF
3 defense response to Gram-negative bacterium GO:0050829 9.95 NOS2 SLC11A1 TLR4 TLR9
4 positive regulation of inflammatory response GO:0050729 9.94 IL2 TLR2 TLR4 TLR9
5 negative regulation of inflammatory response GO:0050728 9.92 FOXP3 IL10 IL2
6 inflammatory response GO:0006954 9.92 CXCL8 IL10 IL27 SLC11A1 TLR2 TLR4
7 positive regulation of JNK cascade GO:0046330 9.91 TLR4 TLR9 TNF
8 regulation of insulin secretion GO:0050796 9.91 IFNG NOS2 TNF
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 IFNG IL2 IL4
10 positive regulation of T cell proliferation GO:0042102 9.9 IFNG IL2 IL4
11 positive regulation of tumor necrosis factor production GO:0032760 9.9 IFNG TLR2 TLR4 TLR9
12 positive regulation of interleukin-6 production GO:0032755 9.89 TLR2 TLR4 TLR9 TNF
13 toll-like receptor signaling pathway GO:0002224 9.88 TLR2 TLR4 TLR9
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 IFNG TLR4 TNF
15 positive regulation of interferon-gamma production GO:0032729 9.88 IL2 SLC11A1 TLR4 TNF
16 cellular response to lipopolysaccharide GO:0071222 9.88 CXCL8 IFNG IL10 NOS2 TLR4 TNF
17 response to bacterium GO:0009617 9.87 IL27 NOS2 SLC11A1 TLR4
18 negative regulation of tumor necrosis factor production GO:0032720 9.86 FOXP3 IL10 TLR4
19 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.85 TLR2 TLR4 TLR9
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 TLR2 TLR4 TNF
21 positive regulation of interleukin-8 production GO:0032757 9.85 TLR2 TLR4 TLR9 TNF
22 positive regulation of interferon-beta production GO:0032728 9.84 TLR2 TLR4 TLR9
23 negative regulation of interferon-gamma production GO:0032689 9.83 FOXP3 IL10 TLR4
24 positive regulation of interleukin-12 production GO:0032735 9.83 IFNG TLR2 TLR4 TLR9
25 negative regulation of growth of symbiont in host GO:0044130 9.82 IFNG IL10 TNF
26 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.81 TLR2 TLR4 TLR9
27 positive regulation of interleukin-10 production GO:0032733 9.81 IL4 TLR2 TLR4 TLR9
28 I-kappaB phosphorylation GO:0007252 9.8 TLR2 TLR4 TLR9
29 regulation of cytokine secretion GO:0050707 9.8 TLR2 TLR4 TLR9
30 defense response to protozoan GO:0042832 9.8 IFNG IL10 IL4 SLC11A1
31 defense response to bacterium GO:0042742 9.8 IFNG IL10 NOS2 SLC11A1 TLR4 TLR9
32 negative regulation of interleukin-17 production GO:0032700 9.79 FOXP3 IFNG TLR4
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.79 IFNG IL2 IL4
34 positive regulation of chemokine biosynthetic process GO:0045080 9.78 IFNG IL4 TNF
35 positive regulation of NF-kappaB import into nucleus GO:0042346 9.78 TLR2 TLR4 TLR9 TNF
36 pentose-phosphate shunt GO:0006098 9.75 PGD TPI1
37 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.75 IFNG IFNGR1
38 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.75 IL27 TLR9
39 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 IL10 TNF
40 positive regulation of B cell proliferation GO:0030890 9.75 IL2 IL4 TLR4
41 cellular response to lipoteichoic acid GO:0071223 9.74 TLR2 TLR4
42 positive regulation of regulatory T cell differentiation GO:0045591 9.74 FOXP3 IL2
43 macrophage activation GO:0042116 9.74 SLC11A1 TLR4
44 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.73 TLR4 TNF
45 endothelial cell apoptotic process GO:0072577 9.73 IL10 TNF
46 positive regulation of chemokine production GO:0032722 9.73 TLR2 TLR4 TLR9 TNF
47 positive regulation of interferon-beta biosynthetic process GO:0045359 9.72 TLR4 TLR9
48 negative regulation of lymphocyte proliferation GO:0050672 9.72 FOXP3 IL2
49 negative regulation of cytokine secretion involved in immune response GO:0002740 9.72 IL10 TNF
50 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.72 IFNG TLR4

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CXCL8 IFNG IL10 IL2 IL27 IL4
2 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Visceral Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....